Jennifer Taylor Veneris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Taylor Veneris has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Panagiotis A. Konstantinopoulos
Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
2 shared publicationsA. Lindsay Frazier
Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Department of Pediatrics, Section of Hematology/Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States of America; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States of America
1 shared publication- Ana Oaknin
Vall d’Hebron Institute of Oncology (VHIO) 7 Medical Oncology Service, Vall d’Hebron Barcelona Hospital Campus, Instituto de Investigación Sanitaria Hospital Universitari Vall d’Hebron (IIS IR-HUVH) Barcelona, Spain
1 shared publication - Ani S. Balmanoukian
The Angeles Clinic and Research Institute, Los Angeles, California
1 shared publication - Carol O'HEar
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, United States
1 shared publication Chandrajit P. Raut
Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States of America
1 shared publication
Latest Publications
- 1 August 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 158 (2) , 467-475
Contemporary management of ovarian germ cell tumors and remaining controversies
- 1 August 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 158 (2) , 467-475
Contemporary management of ovarian germ cell tumors and remaining controversies
- Open Access
- 1 February 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (2) , 488-497
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
- 1 February 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (2) , 488-497
Open AccessChoosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
- 1 August 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 154 (2) , 314-322
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- 1 August 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 154 (2) , 314-322
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 153 (3) , 471-478
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 153 (3) , 471-478
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer
- 1 February 2019
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 29 (2) , 357-364
Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer
Objective High glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 promotes GR activation. The objective of this study was to characterize the relationship of tumor GR gene expression to outcome in ovarian cancer, and to evaluate the relationship of GR expression with BRCA status. Methods Whole exome and whole genome sequencing, gene expression, and clinical data were obtained for high-grade serous ovarian cancers in The Cancer Genome Atlas. Cases with pathogenic somatic or germline BRCA1 or BRCA2 mutations were identified and classified as BRCA mutated. High or low glucocorticoid receptor expression was defined as expression above or below median of the GR/nuclear receptor subfamily 3 C1 (NR3C1) gene level. Overall survival was estimated by the Kaplan-Meier method and compared by Cox regression analysis. Results Combined germline DNA sequencing and tumor microarray expression data were available for 222 high-grade serous ovarian cancer cases. Among these, 47 had a deleterious germline and/or somatic mutation in BRCA1 or BRCA2. In multivariate analysis, high glucocorticoid receptor gene expression was associated with decreased overall survival among ovarian cancer patients, independently of BRCA mutation status. No correlation of GR/NR3C1 gene expression with BRCA mutation status or BRCA1 or BRCA2 mRNA level was observed. Conclusions Increased GR gene expression is associated with decreased overall survival in ovarian cancer patients, independently of BRCA mutation status. High-grade serous ovarian cancers with high GR expression and wild type BRCA have a particularly poor outcome.
- 1 February 2019
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 29 (2) , 357-364
Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer
Objective High glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 promotes GR activation. The objective of this study was to characterize the relationship of tumor GR gene expression to outcome in ovarian cancer, and to evaluate the relationship of GR expression with BRCA status. Methods Whole exome and whole genome sequencing, gene expression, and clinical data were obtained for high-grade serous ovarian cancers in The Cancer Genome Atlas. Cases with pathogenic somatic or germline BRCA1 or BRCA2 mutations were identified and classified as BRCA mutated. High or low glucocorticoid receptor expression was defined as expression above or below median of the GR/nuclear receptor subfamily 3 C1 (NR3C1) gene level. Overall survival was estimated by the Kaplan-Meier method and compared by Cox regression analysis. Results Combined germline DNA sequencing and tumor microarray expression data were available for 222 high-grade serous ovarian cancer cases. Among these, 47 had a deleterious germline and/or somatic mutation in BRCA1 or BRCA2. In multivariate analysis, high glucocorticoid receptor gene expression was associated with decreased overall survival among ovarian cancer patients, independently of BRCA mutation status. No correlation of GR/NR3C1 gene expression with BRCA mutation status or BRCA1 or BRCA2 mRNA level was observed. Conclusions Increased GR gene expression is associated with decreased overall survival in ovarian cancer patients, independently of BRCA mutation status. High-grade serous ovarian cancers with high GR expression and wild type BRCA have a particularly poor outcome.